Effective treatment for botulism requires early clinical recognition. Diagnosis of botulism, including during outbreaks, can be challenging. We assessed combinations of signs and symptoms among confirmed cases and identified sensitive clinical criteria to trigger suspicion. We produced a tool that may facilitate rapid identification of sporadic and outbreak-associated cases.
METHODS

National Botulism Surveillance Database
Clinical data for persons in the United States >12 months of age with suspected botulism are recorded in the National Botulism Surveillance Database at the Centers for Disease Control and Prevention (CDC). Cases are classified as confirmed according to the Council for State and Territorial Epidemiologists case definitions for botulism [7] . We ranked, by frequency, signs and symptoms of botulism among confirmed cases during 2002-2015. We assessed combinations of the most frequent signs and symptoms to define a tool with criteria that is optimally sensitive for a case of botulism. Sensitivity was evaluated by determining the proportion of confirmed cases that fulfilled the criteria. Modifications to the tool were made to account for reasons illnesses were not captured.
Medical Record Abstractions
The National Botulism Surveillance Database data reflect signs and symptoms reported by 1 physician over the phone at the time of consultation. They may differ from those recorded in the more complete hospital medical record and may portray more advanced and recognizable botulism symptoms than those observed earlier in a hospitalization. We therefore abstracted signs and symptoms of botulism from medical records of confirmed cases during 2010-2013 on (1) the first or second day of hospitalization (earliest point in illness when a detailed clinical examination has been performed) and (2) the date of consultation with public health authorities (date that clinical presentation triggered suspicion for botulism) to compare clinical presentations that were often at different time points in the course of illness. The first day of hospitalization was only used for those cases for which consultation with public health occurred on the first day. Sensitivity of the tool was evaluated for the two time points. Record abstraction methods interpreted presence or absence of symptoms differently than surveillance system analysis; therefore, we compared rank orders, not frequencies. Specificity could not be calculated, as the gold standard for botulism diagnosis is clinical diagnosis [8] .
Examining Clinical Features of Botulism in Subpopulations Using Systematic Literature Review Data
Signs and symptoms of botulism that had been abstracted from published case reports and outbreak investigations for systematic reviews were ranked by frequency for nonpediatric patients who were not pregnant, pregnant patients, and pediatric patients to determine if modifications should be made to the tool based on population type. No attempt was made to pool data from CDC surveillance, record abstractions, or systematic reviews because the data were heterogeneous.
Input From Clinical Experts
We consulted with CDC botulism experts and nationally recognized clinical experts in neurology, infectious diseases, emergency medicine, obstetrics, pediatrics, pulmonary and critical care, disaster preparedness, and family practice/internal medicine on the utility of the criteria and made changes based on their recommendations.
RESULTS
We identified 333 confirmed cases in CDC's surveillance database for which 1 sign or symptom was recorded (64% of all the confirmed cases). The 10 most frequent signs and symptoms occurred in 65%-96% of patients and were lack of fever, descending paralysis, dysphagia, weakness or fatigue, ptosis, blurred vision, difficulty speaking, diplopia, change in voice, and shortness of breath (Table 1) . We created 18 combinations of common signs and symptoms of botulism, for which sensitivity ranged from 49% to 96%. We excluded combinations we deemed overly sensitive because they included such nonspecific combinations as afebrile temperature and intact mental status.
We formulated a tool based on 3 specific criteria: (1) afebrile status, unless there is reason not directly related to botulism that explains the fever (eg, infection of a wound); (2) 1 symptom from among a list; and (3) 1 sign from among a list. Intact mental status was removed from the criteria because patients reported in the CDC surveillance database to be alert were described in the medical record abstractions as lethargic, confused, or obtunded, likely because signs such as ptosis and dysarthria were misinterpreted or because of drug intoxication or respiratory failure. While shortness of breath and dry mouth were very commonly reported, we excluded them because they are vague complaints that are nonspecific for botulism. Table 1 shows the ranked frequencies of signs and symptoms by the 5 data sources considered in creating the criteria. a Data for CDC Botulism Surveillance from Rao et al [9] ; systematic reviews from Chatham-Stephens et al [10] , Badell et al [11] , and Griese et al [12] ; and medical record abstractions from unpublished CDC data. b Afebrile were reported temperatures of <38.0°C (<100.4°F).
c Weakness included patients complaining of generalized weakness, fatigue, malaise, poor feeling, lethargy, somnolence, or objectively weak.
d Difficulty speaking/dysarthria included slurred speech.
e Change in voice/dysphonia included any change in the sound of voice, such as hoarseness, and nasal voice.
f Shortness of breath included reports of difficulty breathing, respiratory distress, dyspnea, or apnea.
g Ophthalmoplegia included extraocular palsy such as cranial nerve 3, 4, and 6 palsy.
h Facial palsy included facial weakness, and facial droop.
Clinical experts maintained that persons not accustomed to diagnosing patients independent of a licensed physician (eg, medical students, paramedics, nurses) could, with the help of this objective criteria, quickly and effectively triage patients by suspicion for botulism.
We evaluated signs and symptoms in the pediatric population systematic review by age intervals (Table 2) . Infants (aged <12 months of age) manifested botulism in different ways from older children and adults. Poor feeding, lethargy, and constipation were reported more frequently in infants than among children of other ages. To account for the different way in which infants manifest symptoms of botulism, we added "pooling of secretions or milk" and "poor feeding/poor suck using pacifier/ fatigability while eating" upon input from clinician and infant botulism experts.
The final criteria are shown in Table 3 . The sensitivity of the final criteria for detecting confirmed cases of botulism recorded in CDC's surveillance database was 89% (214/241). Using medical record abstraction data at the time of public health consultation, sensitivity was 87% (86/99); for medical record abstractions within 2 days of hospitalization, sensitivity was 78% (77/99). Thirty-two (13%) cases in the surveillance database were not identified by the tool; review indicated that they were either detected very early in the course due to epidemiologic indicators, were part of an outbreak, or had acute respiratory failure at presentation and no subsequent notation of antecedent signs or symptoms. Fourteen cases were not identified from the medical record abstractions by the tool at both time points; 9 (64%) were detected early in illness course due to epidemiologic indicators, and the remaining 5 (36%) developed a fever of unknown origin or less common signs. Signs and symptoms of botulism among pregnant women appear the same as among nonpediatric patients who were not pregnant.
DISCUSSION
We created a tool to facilitate assessment for botulism consisting of the optimally sensitive combination of signs and symptoms reported in confirmed botulism cases from several data sources. Specificity could not be calculated; we used clinical judgement in seeking to optimize rejection of true nonbotulism cases.
This tool is intended to facilitate consideration of botulism in sporadic cases and outbreaks. It is not intended to provide diagnostic criteria for botulism, but rather to increase suspicion for botulism. Not meeting the criteria does not rule out botulism. It is similar in intent to the American College of Rheumatology's 11 criteria for systemic lupus erythematosus, which helps physicians recognize lupus when 4 criteria are met [13] . Like lupus cases, botulism cases can present with different chief complaints, signs and symptoms, or severity. If the botulism tool's criteria are met, physicians may consider neuroimaging, lumbar puncture, testing of cerebrospinal fluid, and neurology consultation. First and foremost, however, the tool should encourage clinicians to consider seeking expert clinical consultation through their state health department. Public health officials in the United States are available round the clock for consultations with physicians who suspect botulism [1, 2] . Physicians should immediately contact them when botulism is anywhere on a patient's differential diagnosis and an alternative diagnosis cannot quickly be reached.
In the setting of an outbreak, where "worried well" persons may present for evaluation, this tool could facilitate triage. In specific situations, the tool can be augmented with such criteria as exposure to specific food, once public health authorities deem it appropriate. Depending on resource limitations, the tool may also be used to categorize patients by level of care: When medical staffing is adequate but antitoxin supply temporarily limited, patients not fulfilling all criteria may be assigned to monitoring; alternatively, when medical staffing is thin and antitoxin plentiful, they may be assigned to antitoxin treatment. The tool is designed to be used by all levels of healthcare workers if necessary and can be applied in <1 minute. Therefore, it could facilitate patient triage in a mass casualty event.
The sensitivity of our criteria for botulism is similar to that of the lupus criteria, which is 85% [13] . While specificity could not be calculated for our tool, we hypothesize that myasthenia gravis and Miller-Fisher variant of Guillain-Barré syndrome, which are difficult to distinguish clinically from botulism, will also meet the criteria. This tool would support empiric treatment of these illnesses for botulism [5] .
This tool has several limitations. The quality of data in all examined sources was generally poor and incomplete; data were both heterogeneous and overlapping (data from some patients appeared in multiple data sources), precluding pooling of data. Data quality issues compelled use of frequency rank ordering, but precluded any statistical analysis. Publication bias may have affected data presented in systematic reviews and could not be compared [14] . By choosing to use signs and symptoms from the second day of hospitalization, we might have decreased sensitivity for detecting patients with minor complaints. We used clinical judgment in excluding signs or symptoms we deemed overly sensitive and likely to result in overdiagnosis.
In conclusion, we have generated a tool to aid clinical diagnosis of botulism based on the frequency of signs and symptoms present in confirmed botulism patients. The tool is not a diagnostic test or algorithm but can be used to assist clinicians in considering botulism and obtaining antitoxin for treatment. It can also assist in triaging the level of observation and care for patients in an outbreak. 
Notes
